Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) Equity Ratio (2017 - 2025)

Dianthus Therapeutics has reported Equity Ratio over the past 8 years, most recently at 0.95 for Q3 2025.

  • Quarterly results put Equity Ratio at 0.95 for Q3 2025, down 0.79% from a year ago — trailing twelve months through Sep 2025 was 0.95 (down 0.79% YoY), and the annual figure for FY2024 was 0.94, changed 0.12%.
  • Equity Ratio for Q3 2025 was 0.95 at Dianthus Therapeutics, up from 0.93 in the prior quarter.
  • Over the last five years, Equity Ratio for DNTH hit a ceiling of 0.97 in Q1 2024 and a floor of 0.78 in Q2 2023.
  • Median Equity Ratio over the past 4 years was 0.93 (2025), compared with a mean of 0.41.
  • Peak annual rise in Equity Ratio hit 537.69% in 2023, while the deepest fall reached 436.55% in 2023.
  • Dianthus Therapeutics' Equity Ratio stood at 0.53 in 2022, then soared by 276.32% to 0.94 in 2023, then grew by 0.12% to 0.94 in 2024, then increased by 0.41% to 0.95 in 2025.
  • The last three reported values for Equity Ratio were 0.95 (Q3 2025), 0.93 (Q2 2025), and 0.94 (Q1 2025) per Business Quant data.